Skip to main content
Birsoy's groundbreaking research has highlighted key nutrients that cancer cells need to survive, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.

Lifton, who pioneered the use of genomics to identify the basis for diseases, is recognized for a lifetime of contributions in science and mentorship.

A new study reveals how the drug fidaxomicin selectively targets a dangerous pathogen without causing harm to beneficial bacteria. The findings could inform the development of new narrow-spectrum antibiotics for treating other types of infection.

Even after 20 years of upgrades, eight percent of the human genome was still left unsequenced and unstudied. Until now.

With a breadth and depth of experience across academia, the pharmaceutical industry, technology, healthcare, and the financial sector, this latest cohort of trustees brings new skill sets and perspectives to the community.

In studying how bacteria respond to viral infection, scientists are learning that their defense strategies cooperate in ways reminiscent of the elaborate immune systems of animals.

The author of Biased: Uncovering the Hidden Prejudice That Shapes What We See, Think, and Do will be presented with Rockefeller’s prestigious science writing award on April 7.

In response to the Russian invasion of Ukraine on February 24, 2022, Rockefeller University President Richard P. Lifton today released the following statement: The Rockefeller University is a vibrant, international community. Our scientists, students, and staff come from all over the world, inclu...

Read the letter signed by 168 Nobel Prize winners, including five Rockefeller scientists.

One of only a handful of laboratory settings in New York City to receive the designation, the new river campus is recognized for its numerous energy efficient features.